OB-002

· Orion Biotechnology Polska Sp. z o.o.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for OB-002, covering 2025-04-09 to 2025-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Study of OB-002 in Patients With Refractory Metastatic Cancer [Phase 1]